Aradigm Co. (ARDM) Downgraded to "Sell" at Zacks Investment Research

Aradigm Co. (ARDM) Downgraded to "Sell" at Zacks Investment Research


According to Zacks, "Aradigm Corp. is a leading developer of advanced pulmonary drug delivery systems for the treatment of systemic conditions as well as lung diseases. Their hand-held AERx platform is being designed for the rapid and reproducible delivery of a wide range of pharmaceutical drugs and biotech compounds via the lung.



from Biotech News